<DOC>
	<DOCNO>NCT02774837</DOCNO>
	<brief_summary>Chronic Hepatitis B common cause chronic viral liver disease worldwide afflict 350 million person , lead significant morbidity mortality due liver disease HCC 20-40 % infected person . With advent nucleoside analogue , rescue patient significant risk disease progression , circumstance , therapy need long term HBsAg seroclearance uncommon occurrence , stop therapy associate relapse disease hepatitis B flare . The use pegylated interferon show increased HBeAg seroconversion HBsAg seroclearance rate compare nucleoside analogue , however combination nucleos ( ) ide analogue therapy quite disappointing . However recent show combination telbivudine tenofovir response guide therapy design , remarkable 6 % HBsAg seroclearance week 52 patient . Such result require confirmation . There currently unmet need large number patient long term nucleoside analogue therapy achieve HBeAg seroconversion HBsAg seroclearance . Such patient seek alternative long term therapy hence exploration therapeutic strategy attractive . An additional benefit telbivudine surprising improvement renal function study seek examine whether improve renal impairment may see tenofovir . Our study propose examine combination tenofovir telbivudine improve endpoint . Patients fulfil inclusion exclusion criterion randomize tenofovir tenofovir telbivudine ( 1:1 ratio ) . The primary endpoint qHBsAg reduction &gt; 1log week 96 , may predict future HBsAg seroclearance , also secondary endpoint . An additional primary endpoint increase eGFR combination arm compare monotherapy arm . The study aim enroll 146 patient randomize 1:1 ratio ( 73:73 ) patient . Multivariate analysis perform baseline on-treatment factor predict primary outcome .</brief_summary>
	<brief_title>Tenofovir Versus Tenofovir + Telbivudine Chronic Hepatitis B</brief_title>
	<detailed_description>Each subject must sign date study-specific informed consent form ( ICF ) prior participation screening activity . Prospective subject screen 28 day prior administration first dose study drug Day 1 . Screening evaluation use determine eligibility candidate study enrollment . Subjects meet inclusion criterion none exclusion criterion determine screen eligible study . Candidates fail meet eligibility criterion screen evaluation may re-screened one time . Eligible patient end screen randomise 1:1 ratio experimental ( combination ) arm versus control ( mono therapy ) arm . Randomisation perform computer generate random code ( perform Singapore Clinical Research Institute ) mask allocation sequence . There blind therapy study conduct open label study since outcome objectively measurable . After randomisation patient monitor 12 weekly first 24 week , every 24 weekly last visit 96 week . At visit , patient clinical evaluation panel laboratory test : - Hematology : Full blood count , prothrombin time international normalize ratio - Chemistry : Sodium , potassium , creatinine , albumin , alkaline phosphatase , -aspartate transaminase , alanine transaminase , lactate dehydrogenase , total bilirubin , creatine phosphokinase , alphafetoprotein , - Urinalysis : Urine dipstick ( Appearance , color , leucocytes , nitrite , urobilinogen , protein , PH , specific gravity , ketone , bilirubin glucose ) . - Viral serology : HBeAg , anti-HBe , HBsAg , qHBsAg anti-HBs</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Presence positive HBsAg HBV DNA least 6 month . Documented HBeAg positive HBeAg negative . On NA ( lamivudine , adefovir , entecavir , tenofovir combination four ) ≥ 1 year HBV DNA viral load ≤1.0 x 10^5 copies/ml screen ALT ≤ 1 x ULN ( upper limit normal ) U/L A transient elastography ( Fibroscan® ) evaluate fibrosis stage perform screen do past 6 month prior screen . Patient compensate cirrhosis permit study . eGFR ≥ 50 mL/min , calculate CKIEPI equation . Patient agree take investigational drug systemic antiviral , cytotoxic , corticosteroid , immunomodulatory agent Chinese traditional remedy unless clinically indicate . Patient able give write consent prior study start comply study requirement . Women childbearing potential age must negative serum ( ßHCG ) pregnancy test take within 14 day start therapy Lactating/breastfeeding female subject must agree discontinue nurse initiation study medication ( ) . Evidence decompensated liver disease define direct ( conjugate ) bilirubin &gt; 1.2xULN , prothrombin time ( PT ) &gt; 1.5x upper limit normal ( ULN ) , serum albumin &lt; 35 g/L , prior history clinical hepatic decompensation ( egs . ascites , encephalopathy , variceal hemorrhage ) . Evidence hepatocellular carcinoma ( HCC ) . Have follow laboratory test within 4 week study entry : Active coinfection HIV antibody HCV antibody HDV antibody positivity Evidence chronic renal insufficiency define eGFR ( CKDEPI equation &lt; 50 mL/min ) . Previous treatment form interferon , Immunomodulators , systemic cytotoxic agent , systemic corticosteroid within 6 month prior screen . Prolonged exposure know hepatotoxin alcohol drug . History clinically relevant psychiatric disease , seizures , central nervous system dysfunction , severe preexist cardiac , renal , hematological disease medical illness investigator 's opinion might interfere therapy . Current known history malignant disease within 5 year trial entry . Patients history currently know muscle related disease . Liver organ transplant cornea hair . Women pregnant practice adequate birth control measure , lactate . Patients specific contraindication study drug accord Singapore Package Insert .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>nucleoside analogue</keyword>
	<keyword>tenofovir</keyword>
	<keyword>telbivudine</keyword>
	<keyword>quantitative HBsAg</keyword>
	<keyword>combination therapy</keyword>
</DOC>